Results 11 to 20 of about 110,455,116 (191)

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. [PDF]

Cell Death Dis, 2012
Tumours lacking argininosuccinate synthetase-1 (ASS1) are auxotrophic for arginine and sensitive to amino-acid deprivation. Here, we investigated the role of ASS1 as a biomarker of response to the arginine-lowering agent, pegylated arginine deiminase (ADI-PEG20), in lymphoid malignancies.
Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW.   +18 more
europepmc   +6 more sources

Therapeutic arginine starvation in ASS1-deficient cancers inhibits the Warburg effect

Molecular & Cellular Oncology, 2017
Argininosuccinate Synthetase 1 deficiency induces dependence on extracellular arginine for continued cellular growth and survival. Arginine starvation inhibits the Warburg effect and diverts glucose into serine biosynthesis, while simultaneously ...
Jeff C. Kremer, Brian A. Van Tine
doaj   +2 more sources

First report of carglumic acid in a patient with citrullinemia type 1 (argininosuccinate synthetase deficiency)

Journal of Clinical Pharmacy and Therapeutics, 2017
Carglumic acid is a structural analogue of human N-acetylglutamate, which has become an alternative therapeutic option for hyperammonaemia in organic acidaemias such as isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia, and it has been suggested in other urea cycle disorders such as ornithine transcarbamylase deficiency and ...
Kose, E, Kuyum, P, Aksoy, B, Häberle, J, Arslan, N, Ozturk, Y   +5 more
openaire   +7 more sources

Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy

Cancer Letters, 2017
Argininosuccinate synthetase 1 (ASS1) is the rate-limiting enzyme that catalyzes the biosynthesis of arginine (Arg). Many malignant human tumors are auxotrophic for Arg because ASS1 is silenced. ASS1 has been established as a sensor of Arg auxotrophic response and a chemosensitivity marker for Arg starvation therapy. Here, we report that ASS1 is also a
Yan, Long, Wen-Bin, Tsai, Dajuan, Wang, David H, Hawke, Niramol, Savaraj, Lynn G, Feun, Mien-Chie, Hung, Helen H W, Chen, Macus Tien, Kuo   +8 more
openaire   +3 more sources

Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. [PDF]

Theranostics, 2020
Arginine (Arg) deprivation is a promising therapeutic approach for tumors with low argininosuccinate synthetase 1 (ASS1) expression. However, its efficacy as a single agent therapy needs to be improved as resistance is frequently observed. Methods: A tissue microarray was performed to assess ASS1 expression in surgical specimens of pancreatic ductal ...
Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, Li L, Wu N, Moore AM, Zhou L, Yu AC, Dann AM, Elliott IA, Abt ER, Kim W, Dawson DW, Radu CG, Donahue TR.   +17 more
europepmc   +5 more sources

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. [PDF]

J Clin Oncol, 2017
PurposePegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20, cisplatin, and pemetrexed in patients with ASS1 ...
Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW.   +18 more
europepmc   +4 more sources

Loss of Argininosuccinate Synthetase-1 (ASS1) Occurs in Esophageal Adenocarcinoma and Represents a Promising Biomarker for Therapy with Pegargiminase. [PDF]

Cancers (Basel)
Background/Objectives: Despite the introduction of targeted therapies such as Nivolumab, survival outcomes for patients with esophageal adenocarcinoma remain poor. During tumorigenesis, some tumors develop auxotrophy by downregulation of Argininosuccinate Synthetase-1 (ASS1), making them reliant on external arginine supply and thus potentially ...
Knipper K, Lyu SI, Tzitzili E, Spielmann SM, Bruns CJ, Schmidt T, Popp FC, Quaas A.   +7 more
europepmc   +5 more sources

Argininosuccinate synthetase 1 suppression and arginine restriction inhibit cell migration in gastric cancer cell lines. [PDF]

Sci Rep, 2015
AbstractGastric cancer metastasis remains a major cause of cancer-related deaths. There is an urgent need to develop new therapeutic approaches targeting metastatic gastric cancer. Argininosuccinate synthetase 1 (ASS1) expression is increased in gastric cancer.
Shan YS, Hsu HP, Lai MD, Yen MC, Chen WC, Fang JH, Weng TY, Chen YL.   +7 more
europepmc   +5 more sources

Argininosuccinate synthetase 1 depletion produces a metabolic state conducive to herpes simplex virus 1 infection. [PDF]

Proc Natl Acad Sci U S A, 2013
Significance Virus infection can trigger profound alterations in host cell metabolism, but the role of individual enzymes in this process is relatively unstudied. Here, we show that argininosuccinate synthetase 1 (AS1) antagonizes the production of herpes simplex virus 1 (HSV-1) in cultured fibroblasts.
Grady SL, Purdy JG, Rabinowitz JD, Shenk T.   +3 more
europepmc   +4 more sources

Dual Urea Cycle Dysfunction Caused by Coexisting Argininosuccinic Aciduria and Citrin Deficiency: Clinical, Biochemical, and Molecular Insights From an Exceptional Case. [PDF]

JIMD Rep
ABSTRACT Dual inherited defects affecting urea cycle function are exceptionally rare. We report the first case, to our knowledge, of the coexistence of argininosuccinic aciduria (ASA) and citrin deficiency (CD). A girl born to consanguineous Tunisian parents presented at 6 months of age with recurrent seizures, vomiting, developmental delay, and severe
Zribi M, Bhouri M, Khatrouch S, Boudabous H, Häberle J, Abdelmoula MS, Chehida AB.   +6 more
europepmc   +2 more sources